ARAY Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of -3.89% compared to Accuray's net margin of 11.12%. Accuray's return on equity of -35.94% beat Boston Scientific's return on equity of 8.91%.

Accuray has a consensus price target of --, signalling upside risk potential of 215.72%. On the other hand Boston Scientific has an analysts' consensus of $99.14 which suggests that it could grow by 8.87%. Given that Accuray has higher upside potential than Boston Scientific, analysts believe Accuray is more attractive than Boston Scientific.

Accuray has a beta of 1.441, which suggesting that the stock is 44.103% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.799%.

Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Accuray quarterly revenues are $101.5M, which are smaller than Boston Scientific quarterly revenues of $4.2B. Accuray's net income of -$4M is lower than Boston Scientific's net income of $468M. Notably, Accuray's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 75.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.43x versus 8.49x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -3.89% compared to Accuray's net margin of --. Accuray's return on equity of -35.94% beat Perspective Therapeutics's return on equity of --.

Accuray has a consensus price target of --, signalling upside risk potential of 215.72%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 396.92%. Given that Perspective Therapeutics has higher upside potential than Accuray, analysts believe Perspective Therapeutics is more attractive than Accuray.

Accuray has a beta of 1.441, which suggesting that the stock is 44.103% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Accuray quarterly revenues are $101.5M, which are larger than Perspective Therapeutics quarterly revenues of --. Accuray's net income of -$4M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Accuray's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.43x versus 17.55x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -3.89% compared to Accuray's net margin of -4291.67%. Accuray's return on equity of -35.94% beat Catheter Precision's return on equity of -65.84%.

Accuray has a consensus price target of --, signalling upside risk potential of 215.72%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 429.24%. Given that Catheter Precision has higher upside potential than Accuray, analysts believe Catheter Precision is more attractive than Accuray.

Accuray has a beta of 1.441, which suggesting that the stock is 44.103% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Accuray quarterly revenues are $101.5M, which are larger than Catheter Precision quarterly revenues of $96K. Accuray's net income of -$4M is higher than Catheter Precision's net income of -$4.1M. Notably, Accuray's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.43x versus 1.01x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -3.89% compared to Accuray's net margin of -17.98%. Accuray's return on equity of -35.94% beat Xtant Medical Holdings's return on equity of -35.98%.

Accuray has a consensus price target of --, signalling upside risk potential of 215.72%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 469.04%. Given that Xtant Medical Holdings has higher upside potential than Accuray, analysts believe Xtant Medical Holdings is more attractive than Accuray.

Accuray has a beta of 1.441, which suggesting that the stock is 44.103% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Accuray quarterly revenues are $101.5M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. Accuray's net income of -$4M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Accuray's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.43x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.